Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftriaxone + sulbactam + disodium edetate
- Development stage
- Unknown
- Lead developer
- Venus Remedies
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Zydotum is a fixed-dose combination antibiotic developed by Venus Remedies, utilizing their proprietary Antibiotic Adjuvant Entity (AAE) technology. The product is composed of ceftriaxone, a third-generation cephalosporin; sulbactam, a beta-lactamase inhibitor; and disodium edetate (EDTA), which serves as an adjuvant. Ceftriaxone works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). Sulbactam protects ceftriaxone from degradation by inhibiting Class A and some Class C beta-lactamases. The addition of disodium edetate enhances the combination's efficacy by chelating divalent cations, which helps disrupt bacterial biofilms and inhibits metallo-beta-lactamases (Class B) that require zinc for activity. Zydotum is approved for the treatment of various serious infections, including pneumonia, urinary tract infections, meningitis, and skin and soft tissue infections, particularly those caused by multi-drug resistant Gram-negative bacteria.
- Brand names
- ZydotumElores
- Other names
- Ceftriaxone/Sulbactam/EDTA
02
Targets
PBP (Penicillin-binding protein family)NeuraminidaseBacterial extracellular polymeric substance (EPS) matrix and surface-associated metal ionsβ-lactamase
Beyond the preview
Go deeper on ceftriaxone + sulbactam + disodium edetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftriaxone + sulbactam + disodium edetate.